Goa-Based Molbio Diagnostics Files DRHP with SEBI for IPO

Molbio Diagnostics Limited has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI). The company, founded in 2000 and headquartered in Goa, develops point-of-care molecular diagnostic solutions used in India and abroad.

The proposed Initial Public Offering (IPO) will consist of a fresh issue of equity shares worth up to ₹200 crore along with an offer-for-sale (OFS) of up to 1.25 crore shares. Shares will be sold by existing investors, including Exxora Trading LLP and V Sciences Investments Pte Ltd.

IPO Fund Allocation

According to the draft prospectus, ₹99.3 crore from the fresh issue will go towards establishing a new R&D centre, a Centre of Excellence, and related office infrastructure. Around ₹73.5 crore will be used for plant and machinery purchases at the company’s facilities in Goa and Visakhapatnam. The balance is earmarked for working capital and general corporate needs.

Molbio Diagnostics Financial Performance

The company’s revenue stood at ₹3,324.63 million in FY23. It rose to ₹8,365.61 million in FY24 and reached ₹10,204.18 million in FY25, a 22% year-on-year increase. Net profit also turned around during this period, moving from a loss of ₹5.61 million in FY23 to ₹1,019.02 million in FY24. In FY25, profit after tax rose further to ₹1,443.60 million, a 41.7% increase.

Research and Patents

Molbio invested ₹685.7 million in research and development in FY25, about 7% of annual revenue. The company has secured 187 patents worldwide and 16 in India, with more applications pending. Its Truenat platform, a portable RT-PCR device endorsed by the World Health Organisation for tuberculosis detection, supports 42 assays across 30 diseases.

Molbio operates 5 manufacturing facilities: two in Goa, one in Visakhapatnam, and two in Bengaluru. As of March 2025, its annual capacity included 3,600 diagnostic devices and 3.9 crore Truenat test kits, produced through its subsidiary Prognosys Medical Systems.

Read More: Powerica Files Draft IPO Papers With SEBI for ₹1,400 Crore Issue!

Conclusion

The IPO move follows revenue growth, expansion in capacity, and continued investment in research, as the company seeks capital through the equity market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.